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Abstract
Background: Wound healing is impaired in diabetes mellitus, but the mechanisms involved in this process are virtually
unknown. Proteins belonging to the insulin signaling pathway respond to insulin in the skin of rats.
Objective: The purpose of this study was to investigate the regulation of the insulin signaling pathway in wound healing
and skin repair of normal and diabetic rats, and, in parallel, the effect of a topical insulin cream on wound healing and on
the activation of this pathway.
Research Design and Methods: We investigated insulin signaling by immunoblotting during wound healing of control and
diabetic animals with or without topical insulin. Diabetic patients with ulcers were randomized to receive topical insulin or
placebo in a prospective, double-blind and placebo-controlled, randomized clinical trial (NCT 01295177) of wound healing.
Results and Conclusions: Expression of IR, IRS-1, IRS-2, SHC, ERK, and AKT are increased in the tissue of healing wounds
compared to intact skin, suggesting that the insulin signaling pathway may have an important role in this process. These
pathways were attenuated in the wounded skin of diabetic rats, in parallel with an increase in the time of complete wound
healing. Upon topical application of insulin cream, the wound healing time of diabetic animals was normalized, followed by
a reversal of defective insulin signal transduction. In addition, the treatment also increased expression of other proteins,
such as eNOS (also in bone marrow), VEGF, and SDF-1a in wounded skin. In diabetic patients, topical insulin cream markedly
improved wound healing, representing an attractive and cost-free method for treating this devastating complication of
diabetes.
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Introduction
Indolent, non-healing wounds constitute a major problem that
plagues those with diabetes. Approximately 15% of all patients
with diabetes will, at some time, have non-healing wounds, despite
insulin treatment and a meticulously-controlled diet, and this is the
leading cause of lower extremity amputation [1,2]. It is well known
that the basic cellular and molecular mechanisms that result in
wound healing involve cell adhesion, migration, proliferation,
differentiation, and apoptosis [2]. Abnormalities of distinct factors
contribute to defective wound healing in diabetes, including
decreased growth factor production [3], angiogenic response [4,5],
macrophage function [4], collagen accumulation, epidermal
barrier function, and keratinocyte and fibroblast migration and
proliferation [2].
Absolute or relative lack of insulin or insulin action is a hallmark
of diabetes, and defective insulin action in the skin has been
proposed as an important mechanism contributing to wound
healing defects in this disease [6]. Previous data, although not well
controlled, showed that topical insulin accelerates wound healing
in the skin of diabetic rats and humans [7,8,9,10,11,12,13,14,15],
but in these studies no mechanism for this insulin effect was
proposed or investigated. It is known that insulin stimulates the
growth and development of different cell types, and affects
proliferation, migration, and secretion by keratinocytes, endothe-
lial cells, and fibroblasts [12,16,17,18,19]. At least part of the
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effects of insulin in the skin may be via canonical signal
transduction, as previously shown [20], and we suspect that upon
reconstitution of normal insulin signaling in the wounded skin of
diabetic subjects, healing may be corrected.
The purpose of this study was to investigate the regulation of the
insulin signaling pathways in wound healing and skin repair of
normal and diabetic rats and, in parallel, the effect of an insulin
cream on wound healing in these pathways. Since results in
experimental animals were very promising, we also performed a
pilot study employing this insulin cream in a prospective, double-
blind and placebo-controlled, randomized clinical trial of wound
healing in diabetic patients.
Materials and Methods
Materials
Anti-phosphotyrosine (aPY), anti-insulin receptor substrate
(IRS)-1, anti-IRS-2, anti- Src homology 2/a-collagen-related
(SHC), anti-phospho-extracellular signal-regulated protein kinase
(ERK)-1/2, anti-ERK1/2, anti-endothelial nitric oxide synthase
(eNOS), anti-phospho- eNOS, anti-glycogen synthase kinase
(GSK3), anti-phospho-GSK3, anti-serine-threonine kinase
(AKT), anti-stromal cell-derived factor (SDF) 1a, anti-vascular
endothelial growth factor (VEGF), anti-b-actin, and anti-goat- and
anti-rabbit IgG-peroxidase-conjugated antibodies were from Santa
Cruz Technology (Santa Cruz, CA, USA). Anti-phospho-AKT
(serine 473) antibody was from Cell Signaling Technology
(Beverly, MA, USA). Routine reagents were purchased from
Sigma Chemical Co. (St. Louis, MO, USA) unless specified
elsewhere. Protein A was from Amersham (Buckinghamshire,
UK). Materials for immunostaining were from Vector Laborato-
ries Inc. (Burlingame, CA, USA).
Animals
Male Wistar rats were provided by the University of Campinas
Central Breeding Center. Six-week-old male rats were divided
into six groups: 20 control rats with intact skin (CC); 20 control
rats submitted to a skin excision wound (WC); 20 control rats
submitted to a skin excision wound and treated with topical
insulin cream (WCI); 20 rats treated with streptozotocin (STZ) to
induce diabetes (DD); 20 STZ-induced diabetic rats submitted,
after four-seven days, to a skin excision wound (WD); and 20
STZ-induced diabetic rats submitted, after four-seven days, to a
skin excision wound and treated with topical insulin cream
(WDI). All groups received standard rodent chow and water ad
libitum. This study was approved by the Ethical Committee for
Animal Use of the University of Campinas (ID protocol: 1941-1)
The approval is available as supporting information; see
Approval S1.
Skin excision wound and use of insulin cream
Four groups of animals were submitted to only one skin excision
wound per animal (WC, WCI, WD, and WDI). Wounding was
performed under general anesthesia induced by sodium amobar-
bital (15 mg/kg body weight, i.p.), and the animals were used 10–
15 min later, i.e., as soon as anesthesia was assured by the loss of
pedal and corneal reflexes. After shaving the dorsum, a full-
thickness excision wound (4.064.0 mm) was made to the level of
the epidermis and dermis. The wound was not sutured or covered
and healed by secondary intention. Collagenase production is
most prominent at days three and five post-wounding [21], and
the appearance of fibroblasts and the subsequent deposition of
extracellular matrix components such as collagen, elastin, glyco-
proteins, and fibronectin seems to be present 24 hours after
wounding, reaching a maximal amount after 5–6 days, followed by
a gradual decrease after nine days [22]. Fibroblasts in the
granulation tissue of excision wounds are also observed after
three days [23,24]. The excision skin wound was evaluated
clinically every day, and rats were used for experiments after four
or eight days, according to the protocol specified in each
experiment. The insulin cream used was prepared with regular
insulin (0.5 U/g cream) in the pharmacy of our University
Hospital and holds the patent number, PI 0705370-3 (University
of Campinas, Brazil). In preliminary experiments, we used
different concentrations of insulin to prepare the cream (0.0, 0.1,
0.25, 0.5, and 1.0 U/100 g), but the doses that induced the best
effect in wound healing were 0.5 U and 1.0 U/100 g. The dose of
1.0 U/100 g, in some animals, induced alterations in plasma
glucose. Therefore, we used a concentration of 0.5 U/100 g for all
experiments
The cream under study—placebo or with insulin—was applied
locally to cover the excision immediately after wounding (day 0)
and re-applied daily until the end of the experiment (day 4 or day
8). The excision wound of the diabetic animals received placebo
(WD) or the cream with insulin (WDI).
STZ treatment
Overnight-fasted rats were rendered diabetic by a single
intraperitoneal injection of STZ (Sigma; 100 mg/Kg in citric
buffer, pH 4.5) [23]. Control groups received an equivalent
volume of citric buffer, pH 4.5. Rats were used in the experiments
between four and seven days after receiving STZ injection, when
blood glucose reached stable levels over 300 mg/dL [24]. Plasma
glucose levels were determined by the glucose oxidase method
using blood samples collected from the animal tail before the
experiments were performed.
Tissue extraction and immunoblotting
Rats from each group were anesthetized with sodium
amobarbital (15 mg/kg body weight, i.p.) and were used 10–
15 min later, i.e., as soon as anesthesia was assured by the loss of
pedal and corneal reflexes. For evaluation of protein expression
and activation of signal transduction pathways, the skin wound
of anesthetized rats was excised and immediately homogenized
in extraction buffer (1% Triton-X 100, 100 mM Tris, pH 7.4,
containing 100 mM sodium pyrophosphate, 100 mM sodium
fluoride, 10 mM EDTA, 10 mM sodium orthovanadate, 2 mM
PMSF, and 0.1 mg of aprotinin/ml) at 4uC with a Polytron PTA
20S generator (Brinkmann Instruments model PT 10/35)
operated at maximum speed for 30 sec. The extracts were
centrifuged at 15,000 rpm at 4uC in a Beckman 70.1 Ti rotor
(Palo Alto, CA) for 45 min to remove insoluble material, and the
supernatant of these tissues was used for immunoblotting with
antibodies against IR (1:1000), IRS-1 (1:100), IRS-2 (1:100),
phospho-AKT (1:1000), AKT (1:1000), phospho-ERK (1:1000),
ERK (1:1000), phospho-GSK3 (1:1000), GSK3 (1:100), phos-
pho-eNOS (1:100), eNOS (1:100), SHC (1:1000), VEGF-1
(1:1000), SDF-1a (1:200), and SHC (1:1000). Whole tissue
extracts from all animals were mixed with Laemmli buffer and
similar-sized aliquots (20 mg protein) were subjected to SDS-
PAGE. Following transfer to nitrocellulose, blots were probed
with the antibodies described above. The blots were subsequent-
ly incubated with peroxidase-conjugated antibodies (anti-rabbit
or anti-goat). The excision of wounds for tissue extraction and
immunoblotting was performed on day 4 after the incision,
unless specified elsewhere.
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Use of inhibitors of phosphatidyl-inositol 3-kinase (PI3K),
LY294002, and/or of mitogen-activated protein kinase/
extracellular-signal-regulated kinases (MAPK/ERK),
PD98059
In order to evaluate the relevance of the PI3K and MAPK
pathways in the wound healing of diabetic rats, we treated these
animals on day 6 after beginning the use of the insulin cream.
Therefore, there were seven groups of diabetic rats: wounded rats,
wounded rats treated with LY94002, wounded rats treated with
PD98059, wounded rats treated with insulin cream, wounded rats
treated with LY94002 and insulin cream, wounded rats treated
with PD98059 and insulin cream, and wounded rats treated with
LY94002, PD98059 and insulin cream.
Histology and morphometrical analysis
Skin wounds from 3–4 wounded diabetic rats treated with
placebo cream (WD) and wounded diabetic rats treated with
insulin cream (WDI), on the 4th and 8th days after experimental
wounding, were excised and processed for morphological analysis.
Samples were fixed in 4% formaldehyde solution for 8 h at room
temperature and processed for ParaplastH embedding. Transversal
7 mm-thick sections were stained with hematoxylin and eosin (HE).
For morphological analysis of the wounds (HE staining), the tissue
was observed using a 610 objective. Data were compared by
ANOVA and Tukey’s post-test (p,0.05).
Clinical Protocol
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. This study was double-blind and placebo-controlled
in design, and conducted in the State University of Campinas,
Brazil, from January 2004 to September 2007. Eligible patients
were between 18 and 80 years old, both male and female
individuals with type 1 or type 2 diabetes mellitus, and with
wounds that had not healed for at least three months, with serum
creatinine below 1.5 mg/dL. Patients were excluded: if they did
not satisfy the inclusion criteria; if the wounds were infected; if
cellulites, venous stasis, inadequate perfusion, or osteomyelitis
were present; or if the patients were unable to attend the follow-
up. The study was conducted in accordance with the guidelines of
the University of Campinas for clinical trials and the Declaration
of Helsinki. We also obtained ethics approval for the human study
from the University Hospital of the State University of Campinas,
where participants were recruited and human experimentation
was conducted (Clinical Trials identifier: NCT01295177); The
approval is available as supporting information; see Approval S2.
Diabetic patients with chronic foot ulcers for at least three months
were selected for this study with ulcer grade 1 and 2 according to
the Wagner classification [25], with significant soft tissue defects of
the feet. All patients had undergone debridement for the ulcer,
followed by standard moist gauze treatment with 0.9% normal
saline for at least four weeks, resulting in no more than a 15%
reduction in ulcer dimensions. All target wound surfaces were
$2.0 cm and #18 cm in any one dimension after debridement.
Peripheral neuropathy was evaluated by two methods: monofil-
ament testing using a Semmes-Weinstein 5.07 (10 g) monofila-
ment and the base of a vibrating tuning fork (C 128 Hz). From
January 2004 to September 2007, 46 patients were assessed for
eligibility for this study. However, 21 patients were excluded due
to at least one of the following exclusion criteria: presence of
cellulitis (n = 4), venous stasis (n = 5), inadequate perfusion (n = 2),
osteomyelitis (n = 7), and patient’s inability to attend clinics for
follow up (n = 3). All patients included in the study provided a
written informed consent. Twenty-five patients were initially
enrolled; however, three of them did not succeed in completing
the protocol due to inability to attend the clinic (Fig. 1). All
patients included in this study had type 2 diabetes: 11 patients used
subcutaneous insulin and oral anti-diabetic drugs, and 11 patients
used only oral anti-diabetic drugs. Initial laboratory analysis
consisted of leukocyte and platelet count, hemoglobin, glucose,
creatinine, and glycosylated hemoglobin. During the follow-up,
only glucose and glycosylated hemoglobin were evaluated. The
patients were randomly assigned to receive treatment with placebo
cream (cream containing vehicle but without insulin; group P), or
insulin cream (group I) for eight weeks. The patients were
instructed to clean their wounds with sterile gauze and 0.9% sterile
saline daily prior to assessment, putting the cream (placebo or
insulin) and the dressing on afterwards. All wounds were
photographed digitally at the beginning of the study and then at
least every other week during the weekly visits of the patients to the
hospital. Computerized planimetry was used (Texas Health
Science Center at San Antonio ImageTool, version 3.0, as
downloaded from www.ddsdx.uthsca.edu/dig/itdesc.html) to
compare the progression of wound healing in the two groups.
Statistical Analysis
Wound dimensions were calculated in a blinded fashion and
analyzed for homogeneity and significance using SPSS, version
13.0 (SPSS, Inc., Chicago, IL, USA). All continuous variables are
expressed as means 6 SE. One-way analysis of variance
(ANOVA) was used to assess the differences in a continuous
variable between the two groups of patients, and the three or four
groups of animals, using Bonferroni post-test. Post hoc analysis was
performed using Tukey’s test for the histology analysis. All tests
were two-tailed, and the level of significance employed was
P,0.05.
Results
Time-course of expression of insulin signaling proteins in
the wounded skin of rats
Tissue extracts from the excision wounds were obtained at 0, 2,
4, 6, and 8 days after the initial wounding incision, and were used
for immunoblotting with anti-IRS-1 and anti-AKT antibodies, in
order to determine the effect of wound healing on the level of these
proteins in the skin of control rats. Results showed that there is a
consistent increase in both proteins two days after the initial
wound excision, reaching a maximum on day 4, and then
decreasing to levels similar to baseline at day 8, when most wounds
were completely healed (Fig. 2A and 2B). In the skin of diabetic
rats, results followed a similar time-course, but the increases in the
protein levels were much less evident on each day, and on day 8
the wound had not yet healed (Fig. 2C and 2D). In further
experiments, day 4 was used to compare the levels of proteins
involved in the early steps of insulin action between wound healing
in the skin of diabetic and control rats.
Insulin signaling proteins in wounded skin of control and
diabetic rats
An increase in the IR protein level was observed in the wounded
skin of rats, compared to control rats with intact skin
(WC=143625% vs. CC=10068%; P,0.05; Fig. 2E). IR protein
levels were lower in the wounded skin of STZ-diabetic rats
compared to the wounded control rats (WC=143625% vs.
WD=98611%; P,0.05; Fig. 2E). In the wounded skin of control
rats, there was an increase in IRS-1 levels, compared to the intact
skin of control rats (WC=241657% vs. CC=10066%; P,0.05;
Insulin Signaling in Wound Healing in Diabetes
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Fig. 2F). IRS-1 protein levels were decreased in the wounded skin
of diabetic rats, compared to the wounded skin of control rats
(WD=27613% vs. WC=241657%; P,0.05; Fig. 2F) and intact
skin of diabetic rats (WD=27613% vs. DD=78618%; P,0.05;
Fig. 2F). When blots were probed with anti-IRS-2 antibody, we
observed an increase in the protein levels of IRS-2 in the wounded
skin of control rats, compared to the intact skin of control animals
(WC=202617% vs. CC=100615%; P,0.05; Fig. 2G). In the
wounded skin of diabetic rats, IRS-2 protein levels were higher
than in the intact skin of diabetic rats (WD=131614% vs.
DD=97617%; P,0.05; Fig. 2G), but lower than the wounded
skin of control rats (WD=131614% vs. WC=202617%;
P,0.05; Fig. 2G). SHC protein levels were increased in the
wounded skin of control rats compared to the intact skin of control
animals (WC=178611% vs. CC=100612%; P,0.05; Fig. 2H).
SHC protein levels were decreased in the wounded skin of diabetic
rats, compared to the wounded skin of control rats
(WC=178611% vs. WD=15169%; P,0.05; Fig. 2H), but
increased compared to the intact skin of diabetic rats
(WD=15169% vs. DD=7567%; P,0.05; Fig. 2H). When
membranes were probed with anti-AKT antibody, the expression
of this protein was increased in the wounded skin of control rats,
compared to the intact skin of control animals (WC=208610%
vs. CC=100610%; P,0.05; Fig. 2I). AKT protein levels were
decreased in the wounded skin of diabetic rats compared to the
wounded skin of control rats (WD=16568% vs.
WC=208610%; P,0.05; Fig. 2I), but increased compared to
the intact skin of diabetic rats (WD=16568% vs.
DD=168612%; P,0.05; Fig. 2I). ERK1/2 protein levels were
increased in the wounded skin of control rats, compared to the
intact skin of control animals (WC=18966% vs. CC=10063%;
P,0.05; Fig. 2J), but they were decreased in the wounded skin of
diabetic rats when compared to the wounded skin of control rats
(WD=15265% vs. WC=18966%; P,0.05; Fig. 2J) and
increased when compared to the intact skin of diabetic rats
(WD=15265% vs. DD=118614%; P,0.05; Fig. 2J).
Effect of a topical insulin cream on insulin signaling
proteins in wounded skin
In order to establish the dose of insulin of the cream, we
performed a dose-course experiment in diabetic rats, with the
following concentrations of insulin: 0.0, 0.1, 0.25, 0.5, and 1.0 U/
100 g of cream. Wounds were treated with the insulin cream and
measured daily. We observed that insulin concentrations of 0.5 U
and 1.0/100 g presented the best wound healing rate (Fig. 3A).
The dose of 1.0 U/100 g, in some animals, induced alterations in
plasma glucose, and therefore, we used a concentration of 0.5 U/
100 g for all experiments.
We next investigated the effect of an insulin cream on the
wound healing of diabetic rats (Fig. 3B). The effectiveness of the
topical insulin cream treatment in accelerating healing could be
observed in HE-stained sections. Four days after wounding, we
observed the presence of a scab containing many inflammatory
cells, which were mostly neutrophils. The connective tissue of the
Figure 1. Flowchart.
doi:10.1371/journal.pone.0036974.g001
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dermis underneath this scab contained many lymphocytes and
plasma cells. After eight days of wounding, the wound had closed
in all animals treated with WDI; the epidermis was completely
reconstituted, even when a remaining scab was still present at the
wound surface, although skin appendages were absent (Fig. 3C).
The dermis was better organized concerning cells and collagen
fibers arrangement. However, at this stage WD animals did not
have a complete wound closure and keratinocytes were still
migrating to close the wound (Fig. 3C). The dermis was much less
organized than the WDI group.
It is important to mention that the use of insulin cream did not
induce changes in blood glucose levels of control or diabetic
Figure 2. Time-course of IRS-1 and AKT expression following skin wounding in control (A, B) and diabetic animals (C, D). Tissue
protein levels in the intact skin of control (CC) and intact skin of diabetic (DD) rats and in the wounded skin of control (WC) and wounded skin of
diabetic animals (WD). Skin and wound extracts from control and diabetic rats were prepared, as described in Materials and Methods, four days after
the wound incision. Tissue extracts were immunoblotted with (E) anti-IR antibody, (F) anti-IRS-1 antibody, (G) anti-IRS-2 antibody, (H) anti-SHC
antibody, (I) anti-AKT antibody, and (J) anti-ERK1/2 antibody. Equal protein loading was confirmed by reblotting the membranes with anti-b-actin.
Data were compared by ANOVA and Bonferroni post-test, and represented by the mean and standard deviation for each group of scanning
densitometry of six different animals per group. *P,0.05 between groups.
doi:10.1371/journal.pone.0036974.g002
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Figure 3. Macroscopic wound closure in diabetic rats treated with different concentrations of insulin cream. Representative wound
area values during the time-course of 16 days. Values are expressed as mean 6 SEM of at least 10 animals per group. * p,0.05 comparing 0.5 U and
1.0 U vs. 0.0 U, 0.25 U, and 0.1 U of insulin/100 g of cream. (A) Photos showing the time-course of wound healing in rats 0, 4, and 8 days after they
received the insulin cream. (B) Morphology of the wounds after four days (a–b) and eight days (c–d) in rats treated with WD cream (left column - a, c)
or rats treated with WDI cream (right column - b, c). Arrowheads in c show the extremities of the unclosed wound, while d shows complete closure of
the epithelium. EP= epidermis, DE= dermis, SC= scab. Magnification bar in D= 50 mm.
doi:10.1371/journal.pone.0036974.g003
Insulin Signaling in Wound Healing in Diabetes
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animals (Table 1). Results showed that when similar incisions are
performed in control and diabetic rats, the mean healing time is
nine days for controls and 15 days for diabetic animals. Therefore,
the control animals had a 40% increase in the wound healing time
compared to diabetic animals (Fig. 4A). However, when the
topical cream with insulin was used on the wound, the mean
healing time in diabetic animals was similar to that of controls
(Fig. 4A). Notably, the time to complete the healing process in
control rats was unaffected by the topical insulin cream. However,
the percentage of closure showed a difference in the first six days.
Our data showed that the wound area of control rats treated with
insulin cream significantly decreased at several time-points, in
accordance with previous data [9]. We showed that by day 2 and
4, the decrease in wound area induced by insulin was greater than
in the placebo (WCI: 38.2761.5% vs. WC: 2260.45% on day 2,
Figure 4. Days to achieve complete healing in wounded control rats (WC), wounded control rats that received the insulin cream
(WCI), wounded diabetic rats (WD), and wounded diabetic rats that received insulin cream (WDI). (A) Wound area was quantified every
day and expressed as the percentage of the original wound area. (B) Wound extracts were prepared as described in Materials and Methods four days
after the wound incision and were immunoblotted with (C) anti-IRS-1, (D) anti-SHC, (E) anti-phospho-AKT, (F) anti-phospho-ERK1/2, (G) anti-phospho-
GSK3, and (H) anti-phospho-eNOS antibodies. To determine the protein levels of AKT, ERK1/2, GSK3, and eNOS, the membranes were stripped and
reprobed with anti-AKT, -ERK1/2, -GSK3 and -eNOS. Equal protein loading was confirmed by reblotting the membranes with anti-b-actin. Data were
compared by ANOVA and Bonferroni post-test, and represented by the mean and standard deviation for each group of scanning densitometry of six
different animals per group, and the bar graphs represent the ratio of phosphorylation/protein. *p,0.05 between groups; **p,0.05 vs. WCI.
doi:10.1371/journal.pone.0036974.g004
Table 1. Plasma glucose levels of 10 diabetic and 10 control
animals that received the cream with insulin or with placebo.
Time after treatment WC WCI WD WDI
1 h 9365 9862 465626 492626
3 h 9164 9863 502618 523620
6 h 9763 9963 528624 481630
48 h 9167 9562 480630 478635
96 h 9266 9763 461625 482630
The values are represented as the mean 6 SEM of 10 experiments. WC:
wounded control rats; WCI: wounded control rats treated with insulin cream;
WD: diabetic animals treated with placebo cream; WDI: diabetic rats treated
with insulin cream. P,0.05 between control and diabetic rats.
doi:10.1371/journal.pone.0036974.t001
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p,0.05; WCI: 68.6461.2% vs. WC: 49.7561.71% on day 4,
p,0.05). However, although the time to closure was decreased in
control animals treated with insulin, the difference was not
statistically significant (WCI: 8.460.91 days vs. WC: 9.361.4 days,
p = 0.123; Fig. 4B).
The effect of insulin cream was also investigated in the proteins
involved in insulin signaling. Results showed that the blunted
increase in IRS-1, SHC, AKT, and ERK1/2 observed in diabetic
animals, was completely reversed after the use of the cream
(Fig. 4C–F). Downstream of AKT, two signaling proteins are
important for wound healing: GSK3b and eNOS. We also
investigated the regulation of these proteins in the wound healing
of diabetic animals. Results showed that there was a significant
decrease in GSK3b and eNOS protein levels in the wounded skin
of diabetic animals to 5566% and 4668% compared to the
wounded non-diabetic control rats, respectively, and these levels
were completely reversed after topical administration of the insulin
cream (Fig. 4G–H).
Effect of insulin cream with or without inhibitors of PI3K/
AKT and/or MAPK/ERK pathways on wound healing of
diabetic rats
Since our data show an increase in PI3K/AKT and in the
MAPK/ERK pathway, we next investigated the effect of
inhibitors of these pathways during use of the insulin cream for
wound healing (Fig. 5A–C). The results show that the use of
either the inhibitor of PI3K (LY294002) or of MAPK (PD98059),
together with insulin cream, reduced the rate of wound healing
by ,20%, compared to animals treated with insulin cream alone.
It is relevant to mention that the families commonly referred to as
ERKs are activated by parallel protein kinases cascades, named
MAPKs [26,27]. These data suggest that insulin uses both
proteins to improve wound healing. In this regard, the
simultaneous use of the two inhibitors in the insulin cream
almost completely abolished the effect of the insulin cream. The
treatment with LY294002 led to an impairment of the
phosphorylation of AKT (Fig. 5B), a downstream protein of the
PI-3K activation, and the treatment with PD98059 led to the
impairment of the phosphorylation of ERK (Fig. 5C), suggesting
that these inhibitors were effective. The use of these inhibitors in
wounded diabetic rats treated with placebo cream also led to a
trend towards decreasing wound healing rate, although without
statistical significance, reinforcing the data that the pathways
PI3K and ERK are involved in the wound healing process
stimulated by the insulin cream.
Effect of insulin cream on eNOS in bone marrow and on
VEGF and SDF-1a in wound healing in diabetic rats
It has recently been shown that an increase in the migration of
endothelial progenitor cells (EPCs) from bone marrow to wounded
skin is an essential step in wound healing [12,16]. The release of
EPCs involves activation of eNOS in the bone marrow by VEGF,
which is produced in wounded skin, enhancing the mobilization of
EPCs, which are recruited to the skin wound site by an increase in
tissue levels of SDF-1a. We therefore investigated the effect of the
insulin cream on the regulation of this process. Results show that
in the wounded skin of diabetic animals, there were decreases in
VEGF and SDF-1a, and in bone marrow there was also a
decrease in eNOS phosphorylation. These alterations were
completely reversed by topical administration of an insulin cream
in diabetic animals (Fig. 5D–F).
Effect of the topical insulin cream on wound healing in
the skin of diabetic patients
Twenty-two patients, eight females and 14 males, completed the
eight-week study protocol (Fig. 1). The final outcome criterion in
this study was the change in ulcer dimension within the eight
weeks of follow-up. There were no significant differences in clinical
data between patients in the two groups (Table 2). By the end of
the 8th week, the 12 patients that received the placebo cream
showed only a very mild improvement, while the 10 patients that
used the insulin cream presented a significant improvement. The
improvement of the wound healing after the treatment was
obtained between eight and 15 weeks. One-way ANOVA showed
a statistically significant difference among insulin cream and
placebo with regard to the decrease in length (P,0.001), width
(P,0.001), and depth (P,0.001) of the wound (Fig. 6A). Complete
healing occurred in four patients in the insulin-cream group (I) and
in no patients in the placebo group. Pictures of three patients in
group I are shown in Figure 6B.
Since there was an impressive improvement in wound healing in
the patients of group I, we decided to offer the insulin cream to the
patients of group P, after the eight weeks of placebo. In this regard
our final analysis of time for complete healing included all the 22
patients (12 from the placebo group for eight weeks that changed
to insulin, and 10 from the insulin group) that used the insulin
cream until complete healing was achieved. Complete healing
after initiating insulin cream occurred in seven patients at week 8,
in three patients at week 9, in two patients at week 10, in four
patients at week 12, in three patients at week 13, in two patients at
week 14, and in three patients at week 15.
Discussion
The results of the present study show that the insulin signaling
pathways are upregulated in the wounded skin of normal rats, but
in the wounded skin of diabetic animals these upregulations are
blunted. However, when the wounded skin of diabetic rats is
treated with a topical insulin cream, an acceleration of wound
healing occurs, in association with a recovery in the proteins of the
insulin signaling pathways [28].
Our data show that the expression of proteins involved in early
steps of insulin action, i.e., IR/IRS-1,2/AKT, are increased in the
healing tissue of wounds, compared to intact skin. AKT has the
ability to phosphorylate proteins that regulate lipid synthesis,
glycogen synthesis, cell survival, and protein synthesis [18,29,30].
Recently, data from different sources demonstrated that AKT
activation is an important step for VEGF release in skin wounds,
through a post-transcriptional mechanism in keratinocytes [31,32],
and is necessary for vascular maturation and angiogenesis during
cutaneous wound healing [33]. Therefore, the increase in this
signaling pathway observed in the healing skin of wounds might
contribute to the process of tissue repair in skin. Insulin stimulation
of ERK involves the tyrosine phosphorylation of IRS proteins
and/or SHC, which in turn interact with the adapter protein,
Grb2 (growth factor receptor-bound protein-2), recruiting the
Son-of-sevenless (SOS) exchange protein to the plasma membrane
for activation of Ras (one member of a large family of small
molecular weight GTP-binding proteins) [34]. Once activated,
Ras operates as a molecular switch, stimulating a serine kinase
cascade through the stepwise activation of Raf, MEK (protein
kinase that activates MAP kinases), and ERK. Activated ERK can
translocate into the nucleus, where it catalyzes the phosphorylation
of transcription factors, initiating a transcriptional program that
leads to cellular proliferation or differentiation [35,36]. Our results
also show that protein levels of SHC and ERK are increased in the
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wounded skin, suggesting that the ERK signaling pathway can also
play a direct pivotal role in the regulation of cellular growth and
differentiation. It is important to emphasize that ERK activation is
essential for keratinocyte pro-migratory signaling pathways
[3,27,35,37,38,39].
Figure 5. Effect of the inhibitors of PI3K and of ERK. Effect of inhibitors of PI3K (LY294002) and/or ERK (PD98059) on wound
healing on day six after beginning use of the topical cream, represented as a percentage of change in wound area in wounded
diabetic rats (WD), wounded diabetic rats treated with LY294002 (WD+Ly), wounded diabetic rats treated with PD98059 (WD+PD),
wounded diabetic rats treated with insulin (WDI), wounded diabetic rats treated with insulin and Ly (WD+Ly), wounded diabetic
rats treated with insulin and PD (WD+PD), and wounded diabetic rats treated with insulin, Ly and PD (WDI+Ly+PD). (A) AKT
phosphorylation in wound healing. (B) ERK1/2 phosphorylation in wound healing. (C) VEGF-1 protein expression in wound healing. (D) SDF-1a
protein expression in wound healing. (E) eNOS phosphorylation and eNOS protein expression in wound healing. (F) Equal protein loading was
confirmed by reblotting the membranes with anti-b-actin. Data were compared by ANOVA and Bonferroni post-test, and represented by the mean
and standard deviation for each group of scanning densitometry of six different animals per group. *P,0.05 between groups; **P,0.05 vs. WD vs.
WD+Ly vs. WD+PD; ***P,0.05 vs. WDI.
doi:10.1371/journal.pone.0036974.g005
Table 2. Clinical and laboratory characteristics of diabetic patients, treated with placebo (P) or insulin cream (I).
Variable N (%) Mean (± SD)
P I
Male 14 (63.64)
Female 8 (36.36)
Age (years) 64.0 (610.5) 62.0 (611.1)
Time since diagnosis of diabetes mellitus (years) 8.6 (66.1) 9.9 (67.7)
Body mass index {weight (kg)/height(m)2} 28.5 (66.2) 29.7 (64.9)
Glycosylated hemoglobin 8.1 (62.8) 7.9 (62.4)
Fasting glycemia 179.6 (672.2) 170.8 (666.3)
Creatinine 1.0 (60.2) 0.9(60.16)
Leukocytes 5600 (69000) 5870 (61.100)
There were no significant differences between the groups, according to a paired t-test.
doi:10.1371/journal.pone.0036974.t002
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Furthermore, we observed that tissue expression of these
proteins is attenuated in wounded skin of diabetic rats compared
with the increase observed in wounded skin of control rats.
Therefore, we can suggest that the abnormal insulin signaling
observed in wounded skin of diabetic rats might contribute to the
impaired wound healing observed as a complication of diabetes.
There are probably several mechanisms that can attenuate insulin
signaling in the wounded skin of the diabetic. First, it is known that
elevated levels of glucose affect insulin signaling by regulating the
expression of several genes, including the insulin receptor gene, at
both the transcriptional and translational levels [40]. Moreover,
hyperglycemia was shown to inhibit insulin action as a result of
serine phosphorylation of IRS through a PKC-mediated mecha-
nism, which may in turn increase the degradation of IRS proteins
[41,42].
In accordance with a downregulation of insulin signaling
proteins in wound healing of diabetic animals, Goren et al.
showed that insulin signaling proteins, including IRb, IRS-1, IRS-
2, and phosphorylated GSK3b were almost absent in acutely
healing skin from ob/ob mice [43]. It is important to mention that
in this type 2 diabetes obese animal model, leptin is absent and
there is an increase in circulating TNFa. In this regard, this
previous study showed that the administration of leptin or the
infusion of anti-TNFa reversed the alterations in insulin signaling
Figure 6. Percentage of change of ulcers in patients. (A) Change in length, width, and depth of ulcers in the two groups of diabetic patients
that received the insulin cream (I) or placebo (P). (B) Photos showing the time-course of wound healing in patients 0, 2, 4, 6, 9, 12, and 13 weeks after
receiving the insulin cream. *P,0.001 vs. placebo.
doi:10.1371/journal.pone.0036974.g006
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proteins and improved wound healing. Our data, by using a
hypoinsulinemic animal model of diabetes showed that not only
IR/IRSs/PI3k/Akt pathway but also the SHC/ERK pathway are
downregulated in the wounded skin of diabetic animal. In
addition, we show that the insulin cream can completely restore
these alterations.
A previous study showed that diabetic rat serum stimulated
collagen synthesis to a significantly lesser extent than normal rat
serum [44]. On the other hand, topical use of insulin improves
wound healing [7] and it is known that insulin stimulates
[3H]thymidine incorporation into human skin fibroblasts
[45,46]. In addition, insulin strongly and specifically stimulates
collagen synthesis in skin fibroblasts [44]. These data encouraged
us to prepare a cream containing insulin, with the aim of
accelerating wound healing in diabetes. Our data shows that the
insulin cream normalizes the wound healing in the skin of diabetic
rats and, in parallel, induces a recovery in the tissue level of all
proteins involved in early steps of insulin action.
The molecular mechanisms by which insulin accelerates wound
healing in diabetes seem to be many. The increase in proteins
involved in the early steps of insulin action may play a role, since
AKT and ERK have important growth and development effects.
Additionally, the use of inhibitors of these pathways reduced the
effect of insulin, suggesting that insulin uses both pathways to
increase wound healing. At least two important substrates of
AKT—GSK3b and eNOS—may have an important role in
wound healing [30,47]. GSK3b, when phosphorylated by AKT,
has a reduced activity. It was recently demonstrated that mice
harboring a fibroblast-specific GSK3b deficiency exhibit elevated
collagen production, reduced apoptosis, and accelerated wound
closure [47]. Thus, an increase in GSK3b phosphorylation, and a
consequent reduction in its activity, may be one mechanism by
which AKT can increase wound healing. AKT can also
phosphorylate eNOS and promote NO production [48,49],
enhancing blood flow, cell survival, morphogenesis, and angio-
genesis, even in the setting of ischemia [50,51]. The multitude of
AKT substrates and their described effects on various cellular
functions may contribute, at least in part, to the beneficial effect of
the insulin cream in wound healing, since this cream increases
AKT protein expression and phosphorylation in the wounded skin
of diabetic rats. Our data clearly show that the use of this insulin
cream is an efficient manner to activate the AKT and ERK
pathways, which are essential in the control of wound healing
(Fig. 7).
It is now well established that an increase in the migration of
EPCs from bone marrow to wounded skin accelerates wound
healing. The regulation of this process is complex and involves
activation of eNOS in the bone marrow by VEGF (produced in
the wounded skin), enhancing the mobilization of EPC, which is
recruited to the cutaneous wound site by an increase in tissue levels
of SDF-1a [18,19]. Our data, in accordance with results of a
previous paper [19], showed that this complex process is
downregulated in diabetic rats. However, interestingly, the use
of an insulin cream in wounded skin, increased the tissue
expression of VEGF, increased eNOS phosphorylation in the
bone marrow, and increased SDF-1a in the wounded skin of
diabetic animals. It is important to emphasize that the treatment of
diabetic animals with subcutaneous insulin for one week was not
able to restore eNOS phosphorylation or increase SDF-1a in the
wounded skin of diabetic animals (data not shown).
In diabetic patients, growth factors are major technological
advances that promise to change the face of wound healing
[8,52,53,54]. The most important growth factors used are
recombinant human platelet-derived growth factor-BB (PDGF),
granulocyte colony-stimulating factor (CSF), and epidermal
growth factor. Many clinical trials have used these growth factors
Figure 7. Effect of insulin on cellular and molecular mechanisms of wound healing in diabetes. Insulin induces activation of IR/SHC/ERK
and IR/IRS/PI3K/AKT pathways in wound healing, which are canonical insulin signaling pathways. On the upper right-hand side, AKT is shown to
increase VEGF (probably from macrophages, fibroblasts and epithelial cells) that will induce the phosphorylation and activation of eNOS in bone
marrow, with consequent mobilization of EPCs to the circulation. SDF1a induces the homing of these EPC at the injury site, where they participate in
neovasculogenesis. Insulin cream increased VEGF and SDF1a tissue expression in wound healing, and also increased eNOS phosphorylation in the
bone marrow of an animal model of diabetes.
doi:10.1371/journal.pone.0036974.g007
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and shown only a mild improvement in wound healing [53,54]. In
addition, these growth factors are usually very expensive. Our
results, with diabetic patients randomized to receive topical insulin
or placebo in a prospective, double-blind and placebo-controlled
clinical trial, show that the application of a cream containing
insulin is able to significantly improve wound healing in these
patients and, although the patients had very different sizes of
ulcers, we observed complete healing at week 15 in all the 22
patients that used this cream. Previous pilot studies in animals or
humans have employed topical insulin to accelerate wound
healing in diabetes and, although these studies were not well
designed, they all show an effect of insulin on this process
[7,8,9,10,11,12,13,14,15,55]. The insulin cream we made allowed
us to prepare a homogenous cream, and improved the adherence
of the cream to the surface of the wound. This product is practical
and easy to use and, as demonstrated, is completely safe and did
not induce hypoglycemia.
In contrast to other growth factors, insulin is much cheaper and
available everywhere. Thus, with these results, we may suggest
that a cream containing insulin is a cheaper and efficient
adjunctive active wound therapy for diabetic patients.
In summary, our results show that tissue expression of IR, IRS-
1, IRS-2, SHC, ERK, and AKT are increased in wound healing
tissue, compared to intact skin, suggesting that the insulin signaling
pathway may have an important role in wound healing. We also
found that these pathways were attenuated in the wounded skin of
diabetic rats, when compared to the wounded skin of normal rats,
in parallel with an increase in the time for wound closure.
Therefore, an insulin cream administered on the wound skin of
diabetic animals, improved wound healing, and reversed the
reductions observed in proteins of the insulin signaling pathways.
In addition, the treatment also increased the expression of other
proteins, such as eNOS (also in bone marrow), VEGF, and SDF-
1a in wounded skin. In diabetic patients, this insulin cream was
able to improve wound healing, offering a genuine, cheap and
efficient treatment for this devastating complication of diabetes.
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